- Home
- CKPT vs GROY Comparison
CKPT vs GROY Comparison
Compare CKPT & GROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- GROY
- Stock Information
- Founded
- CKPT 2014
- GROY 2020
- Country
- CKPT United States
- GROY Canada
- Employees
- CKPT N/A
- GROY N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- GROY
- Sector
- CKPT Health Care
- GROY
- Exchange
- CKPT Nasdaq
- GROY Nasdaq
- Market Cap
- CKPT 172.4M
- GROY 206.6M
- IPO Year
- CKPT 2017
- GROY 2021
- Fundamental
- Price
- CKPT $4.04
- GROY $1.43
- Analyst Decision
- CKPT Buy
- GROY Strong Buy
- Analyst Count
- CKPT 3
- GROY 4
- Target Price
- CKPT $4.33
- GROY $3.31
- AVG Volume (30 Days)
- CKPT 5.6M
- GROY 1.4M
- Earning Date
- CKPT 03-28-2025
- GROY 03-20-2025
- Dividend Yield
- CKPT N/A
- GROY N/A
- EPS Growth
- CKPT N/A
- GROY N/A
- EPS
- CKPT N/A
- GROY N/A
- Revenue
- CKPT $41,000.00
- GROY $10,103,000.00
- Revenue This Year
- CKPT $102,182.93
- GROY $145.05
- Revenue Next Year
- CKPT $351.71
- GROY $48.73
- P/E Ratio
- CKPT N/A
- GROY N/A
- Revenue Growth
- CKPT N/A
- GROY 231.46
- 52 Week Low
- CKPT $1.38
- GROY $1.16
- 52 Week High
- CKPT $4.50
- GROY $2.21
- Technical
- Relative Strength Index (RSI)
- CKPT 65.90
- GROY 50.11
- Support Level
- CKPT $2.37
- GROY $1.39
- Resistance Level
- CKPT $4.07
- GROY $1.51
- Average True Range (ATR)
- CKPT 0.03
- GROY 0.07
- MACD
- CKPT 0.01
- GROY -0.01
- Stochastic Oscillator
- CKPT 70.00
- GROY 45.31
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and streaming company. It offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests.